These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. FcRn: from molecular interactions to regulation of IgG pharmacokinetics and functions. Challa DK; Velmurugan R; Ober RJ; Sally Ward E Curr Top Microbiol Immunol; 2014; 382():249-72. PubMed ID: 25116104 [TBL] [Abstract][Full Text] [Related]
23. Conformational Destabilization of Immunoglobulin G Increases the Low pH Binding Affinity with the Neonatal Fc Receptor. Walters BT; Jensen PF; Larraillet V; Lin K; Patapoff T; Schlothauer T; Rand KD; Zhang J J Biol Chem; 2016 Jan; 291(4):1817-1825. PubMed ID: 26627822 [TBL] [Abstract][Full Text] [Related]
24. Evaluation of an FcRn affinity chromatographic method for IgG1-type antibodies and evaluation of IgG variants. Cymer F; Schlothauer T; Knaupp A; Beck H Bioanalysis; 2017 Sep; 9(17):1305-1317. PubMed ID: 28901177 [TBL] [Abstract][Full Text] [Related]
25. FcRn affinity-pharmacokinetic relationship of five human IgG4 antibodies engineered for improved in vitro FcRn binding properties in cynomolgus monkeys. Datta-Mannan A; Chow CK; Dickinson C; Driver D; Lu J; Witcher DR; Wroblewski VJ Drug Metab Dispos; 2012 Aug; 40(8):1545-55. PubMed ID: 22584253 [TBL] [Abstract][Full Text] [Related]
26. The influence of antibody engineering on Fc conformation and Fc receptor binding properties: Analysis of FcRn-binding engineered antibodies and an Fc fusion protein. Suzuki T; Hashii N; Tada M; Ishii-Watabe A MAbs; 2021; 13(1):1923366. PubMed ID: 34030575 [TBL] [Abstract][Full Text] [Related]
27. Evaluation of a catenary PBPK model for predicting the in vivo disposition of mAbs engineered for high-affinity binding to FcRn. Chen Y; Balthasar JP AAPS J; 2012 Dec; 14(4):850-9. PubMed ID: 22956476 [TBL] [Abstract][Full Text] [Related]
28. Engineering the Fc region of immunoglobulin G to modulate in vivo antibody levels. Vaccaro C; Zhou J; Ober RJ; Ward ES Nat Biotechnol; 2005 Oct; 23(10):1283-8. PubMed ID: 16186811 [TBL] [Abstract][Full Text] [Related]
29. Neonatal Fc receptor and IgG-based therapeutics. Kuo TT; Aveson VG MAbs; 2011; 3(5):422-30. PubMed ID: 22048693 [TBL] [Abstract][Full Text] [Related]
30. The interplay of non-specific binding, target-mediated clearance and FcRn interactions on the pharmacokinetics of humanized antibodies. Datta-Mannan A; Lu J; Witcher DR; Leung D; Tang Y; Wroblewski VJ MAbs; 2015; 7(6):1084-93. PubMed ID: 26337808 [TBL] [Abstract][Full Text] [Related]
31. Human IgG lacking effector functions demonstrate lower FcRn-binding and reduced transplacental transport. Stapleton NM; Armstrong-Fisher SS; Andersen JT; van der Schoot CE; Porter C; Page KR; Falconer D; de Haas M; Williamson LM; Clark MR; Vidarsson G; Armour KL Mol Immunol; 2018 Mar; 95():1-9. PubMed ID: 29367080 [TBL] [Abstract][Full Text] [Related]
32. FcRn, but not FcγRs, drives maternal-fetal transplacental transport of human IgG antibodies. Borghi S; Bournazos S; Thulin NK; Li C; Gajewski A; Sherwood RW; Zhang S; Harris E; Jagannathan P; Wang LX; Ravetch JV; Wang TT Proc Natl Acad Sci U S A; 2020 Jun; 117(23):12943-12951. PubMed ID: 32461366 [TBL] [Abstract][Full Text] [Related]
33. An Chung S; Nguyen V; Lin YL; Lafrance-Vanasse J; Scales SJ; Lin K; Deng R; Williams K; Sperinde G; Li JJ; Zheng K; Sukumaran S; Tesar D; Ernst JA; Fischer S; Lazar GA; Prabhu S; Song A MAbs; 2019 Jul; 11(5):942-955. PubMed ID: 30982394 [TBL] [Abstract][Full Text] [Related]
34. Methods to engineer and identify IgG1 variants with improved FcRn binding or effector function. Kelley RF; Meng YG Methods Mol Biol; 2012; 901():277-93. PubMed ID: 22723108 [TBL] [Abstract][Full Text] [Related]
35. Characterization of the interactions of rabbit neonatal Fc receptor (FcRn) with rabbit and human IgG isotypes. Szikora B; Hiripi L; Bender B; Kacskovics I; Iliás A PLoS One; 2017; 12(9):e0185662. PubMed ID: 28957416 [TBL] [Abstract][Full Text] [Related]
36. A novel approach to investigate the effect of methionine oxidation on pharmacokinetic properties of therapeutic antibodies. Stracke J; Emrich T; Rueger P; Schlothauer T; Kling L; Knaupp A; Hertenberger H; Wolfert A; Spick C; Lau W; Drabner G; Reiff U; Koll H; Papadimitriou A MAbs; 2014; 6(5):1229-42. PubMed ID: 25517308 [TBL] [Abstract][Full Text] [Related]
37. Quantitative cumulative biodistribution of antibodies in mice: effect of modulating binding affinity to the neonatal Fc receptor. Yip V; Palma E; Tesar DB; Mundo EE; Bumbaca D; Torres EK; Reyes NA; Shen BQ; Fielder PJ; Prabhu S; Khawli LA; Boswell CA MAbs; 2014; 6(3):689-96. PubMed ID: 24572100 [TBL] [Abstract][Full Text] [Related]
38. Field flow fractionation for assessing neonatal Fc receptor and Fcγ receptor binding to monoclonal antibodies in solution. Pollastrini J; Dillon TM; Bondarenko P; Chou RY Anal Biochem; 2011 Jul; 414(1):88-98. PubMed ID: 21385563 [TBL] [Abstract][Full Text] [Related]
39. The neonatal Fc receptor: Key to homeostasic control of IgG and IgG-related biopharmaceuticals. Baldwin WM; Valujskikh A; Fairchild RL Am J Transplant; 2019 Jul; 19(7):1881-1887. PubMed ID: 30903736 [TBL] [Abstract][Full Text] [Related]
40. The effect of the neonatal Fc receptor on human IgG biodistribution in mice. Chen N; Wang W; Fauty S; Fang Y; Hamuro L; Hussain A; Prueksaritanont T MAbs; 2014; 6(2):502-8. PubMed ID: 24492305 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]